Sosa Cuevas, E., Ouaguia, L., Mouret, S., Charles, J., De Fraipont, F., Manches, O., . . . Aspord, C. (2020). BDCA1(+) cDC2s, BDCA2(+) pDCs and BDCA3(+) cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients. Clin Transl Immunology.
Chicago Stili AlıntıSosa Cuevas, Eleonora, et al. "BDCA1(+) CDC2s, BDCA2(+) PDCs and BDCA3(+) CDC1s Reveal Distinct Pathophysiologic Features and Impact On Clinical Outcomes in Melanoma Patients." Clin Transl Immunology 2020.
MLA AlıntıSosa Cuevas, Eleonora, et al. "BDCA1(+) CDC2s, BDCA2(+) PDCs and BDCA3(+) CDC1s Reveal Distinct Pathophysiologic Features and Impact On Clinical Outcomes in Melanoma Patients." Clin Transl Immunology 2020.
Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..